Medifast Inc
NYSE:MED

  • LAST PRICE
    18.4100
  • TODAY'S CHANGE (%)
    0.1100 (0.6011%)
  • Bid / Lots
    18.1400/ 1
  • Ask / Lots
    18.4900/ 1
  • Open / Previous Close
    18.4200 / 18.3000
  • Day Range
    18.0200
    18.6500
  • 52 Week Range
    17.0692
    76.4200
  • Volume
    143,538

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 5, 2024

  • Nov 4, 2024

      Show headlines and story abstract

    • 4:16PM ET on Monday Nov 04, 2024 by MT Newswires
      Companies Mentioned: MED
      04:16 PM EST, 11/04/2024 (MT Newswires) -- ...

    • 4:16PM ET on Monday Nov 04, 2024 by MT Newswires
      Companies Mentioned: MED
      04:16 PM EST, 11/04/2024 (MT Newswires) -- ...

    • 4:05PM ET on Monday Nov 04, 2024 by Dow Jones
      Companies Mentioned: MED
      Selling, general, and administrative 151,868 -- -- 151,868 Income from operations 25,509 -- -- 25,509 Other income 1,040 -- -- 1,040 Provision for income taxes 3,418 -- -- 3,418 Net income 23,131 -- -- 23,131 Diluted earnings per share(1) 2.12 -- -- 2.12 Nine Months Ended September 30, 2024 --------------------------------------------------------------------------------------- Supply Chain Unrealized Optimization and Loss on Restructuring of Investment External OPTAVIA in LifeMD LifeMD Prepaid Manufacturing Convention Common Services GAAP Agreements Cancellation Stock Amortization Non-GAAP -------- ------------------ ---------------- ----------- ---------------- -------- Cost of sales $127,056 $ (2,579) $ -- $ -- $ -- $124,477 Gross profit 356,404 2,579 -- -- -- 358,983 Selling, general, and administrative 354,235 (12,502) (3,000) (5,000) 333,733 Income from operations 2,169 15,081 3,000 -- 5,000 25,250 Other income 343 -- -- 3,734 -- 4,077 Provision for income taxes 1,222 3,770 750 934 1,250 7,926 Net income 1,290 11,311 2,250 2,800 3,750 21,400 Diluted earnings per share(1) 0.12 1.03 0.21 0.26 0.34 1.95 Nine Months Ended September 30, 2023 ------------------------------------------------------------------------------- Supply Chain Optimization Unrealized and Loss on Restructuring Investment LifeMD of External OPTAVIA in LifeMD Prepaid Manufacturing Convention Common Services GAAP Agreements Cancellation Stock Amortization Non-GAAP -------- -------------- ------------- ----------- ------------- ---------- Cost of sales $246,558 $ -- $ -- $ -- $ -- $ 246,558 Gross profit 634,481 -- -- -- -- 634,481 Selling, general, and administrative 516,755 -- -- -- -- 516,755 Income from operations 117,726 -- -- -- -- 117,726 Other income 1,269 -- -- -- -- 1,269 Provision for income taxes 25,615 -- -- -- -- 25,615 Net income 93,380 -- -- -- -- 93,380 Diluted earnings per share(1) 8.55 -- -- -- -- 8.55 (1) The weighted-average diluted shares outstanding used in the calculation of these non-GAAP financial measures are the same as the weighted-average shares outstanding used in the calculation of the reported per share amounts.

    • 4:05PM ET on Monday Nov 04, 2024 by Dow Jones
      Companies Mentioned: MED
      Selling, general, and administrative 151,868 -- -- 151,868 Income from operations 25,509 -- -- 25,509 Other income 1,040 -- -- 1,040 Provision for income taxes 3,418 -- -- 3,418 Net income 23,131 -- -- 23,131 Diluted earnings per share(1) 2.12 -- -- 2.12 Nine Months Ended September 30, 2024 --------------------------------------------------------------------------------------- Supply Chain Unrealized Optimization and Loss on Restructuring of Investment External OPTAVIA in LifeMD LifeMD Prepaid Manufacturing Convention Common Services GAAP Agreements Cancellation Stock Amortization Non-GAAP -------- ------------------ ---------------- ----------- ---------------- -------- Cost of sales $127,056 $ (2,579) $ -- $ -- $ -- $124,477 Gross profit 356,404 2,579 -- -- -- 358,983 Selling, general, and administrative 354,235 (12,502) (3,000) (5,000) 333,733 Income from operations 2,169 15,081 3,000 -- 5,000 25,250 Other income 343 -- -- 3,734 -- 4,077 Provision for income taxes 1,222 3,770 750 934 1,250 7,926 Net income 1,290 11,311 2,250 2,800 3,750 21,400 Diluted earnings per share(1) 0.12 1.03 0.21 0.26 0.34 1.95 Nine Months Ended September 30, 2023 ------------------------------------------------------------------------------- Supply Chain Optimization Unrealized and Loss on Restructuring Investment LifeMD of External OPTAVIA in LifeMD Prepaid Manufacturing Convention Common Services GAAP Agreements Cancellation Stock Amortization Non-GAAP -------- -------------- ------------- ----------- ------------- ---------- Cost of sales $246,558 $ -- $ -- $ -- $ -- $ 246,558 Gross profit 634,481 -- -- -- -- 634,481 Selling, general, and administrative 516,755 -- -- -- -- 516,755 Income from operations 117,726 -- -- -- -- 117,726 Other income 1,269 -- -- -- -- 1,269 Provision for income taxes 25,615 -- -- -- -- 25,615 Net income 93,380 -- -- -- -- 93,380 Diluted earnings per share(1) 8.55 -- -- -- -- 8.55 (1) The weighted-average diluted shares outstanding used in the calculation of these non-GAAP financial measures are the same as the weighted-average shares outstanding used in the calculation of the reported per share amounts.

Peers Headlines